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Near-Infrared Imaging of Adoptive Immune Cell Therapy
in Breast Cancer Model Using Cell Membrane Labeling
Fatma M. Youniss1, Gobalakrishnan Sundaresan1, Laura J. Graham2, Li Wang1, Collin R. Berry1,
Gajanan K. Dewkar1, Purnima Jose1, Harry D. Bear2,3, Jamal Zweit1,3*
1 Department of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America, 2 Department of Surgery,
Division of Surgical Oncology, Virginia Commonwealth University, Richmond, Virginia, United States of America, 3 Massey Cancer Center, Virginia Commonwealth
University, Richmond, Virginia, United States of America

Abstract
The overall objective of this study is to non-invasively image and assess tumor targeting and retention of directly labeled Tlymphocytes following their adoptive transfer in mice. T-lymphocytes obtained from draining lymph nodes of 4T1 (murine
breast cancer cell) sensitized BALB/C mice were activated in-vitro with Bryostatin/Ionomycin for 18 hours, and were grown
in the presence of Interleukin-2 for 6 days. T-lymphocytes were then directly labeled with 1,1-dioctadecyltetramethyl
indotricarbocyanine Iodide (DiR), a lipophilic near infrared fluorescent dye that labels the cell membrane. Assays for viability,
proliferation, and function of labeled T-lymphocytes showed that they were unaffected by DiR labeling. The DiR labeled
cells were injected via tail vein in mice bearing 4T1 tumors in the flank. In some cases labeled 4T1 specific T-lymphocytes
were injected a week before 4T1 tumor cell implantation. Multi-spectral in vivo fluorescence imaging was done to subtract
the autofluorescence and isolate the near infrared signal carried by the T-lymphocytes. In recipient mice with established
4T1 tumors, labeled 4T1 specific T-lymphocytes showed marked tumor retention, which peaked 6 days post infusion and
persisted at the tumor site for up to 3 weeks. When 4T1 tumor cells were implanted 1-week post-infusion of labeled Tlymphocytes, T-lymphocytes responded to the immunologic challenge and accumulated at the site of 4T1 cell implantation
within two hours and the signal persisted for 2 more weeks. Tumor accumulation of labeled 4T1 specific T-lymphocytes was
absent in mice bearing Meth A sarcoma tumors. When lysate of 4T1 specific labeled T-lymphocytes was injected into 4T1
tumor bearing mice the near infrared signal was not detected at the tumor site. In conclusion, our validated results confirm
that the near infrared signal detected at the tumor site represents the DiR labeled 4T1 specific viable T-lymphocytes and
their response to immunologic challenge can be imaged in vivo.
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treatment of melanoma patients. Their results showed that
adoptively transferred T-cell clones persist in vivo and preferentially localize to tumor sites and mediate an antigen-specific
immune response characterized by metastases regression in 8 of 10
patients. Another study showed that the re-infusion of engineered
lymphocytes to express melanoma-specific T cell receptor (TCR)
induced regression in 13% of patients [3]. The success of AIT
relies on the ex vivo manipulation of tumor specific T-lymphocytes
to produce a large number of cells with optimized anti-tumor
effector functions [4]. We have previously shown that in vitro
treatment of tumor antigen sensitized draining lymph node (DLN)
cells with bryostatin and ionomycin (B/I) selectively activates
antigen-sensitized T lymphocytes that can induce regression of
several different murine tumors, either primary or metastatic, and
can confer long-term resistance to re-challenge [5–7]. Several
groups are also investigating and exploring the possibility of using
cocktail of growth factors during ex vivo expansion of

Introduction
Cancer treatment by adoptive immune cell therapy (AIT) is a
form of immunotherapy that relies on the in vitro activation and/
or expansion of immune cells. In this approach, immune cells,
particularly CD8+ T lymphocytes, can potentially be harvested
from a tumor-bearing patient, then activated and/or expanded in
vitro in the presence of cytokines and other growth factors, and
then transferred back into the same patient to induce tumor
regression. AIT allows the in vitro generation and activation of Tlymphocytes away from the immunosuppressive tumor microenvironment, thereby providing optimum conditions for potent antitumor activity. Dudley and colleagues [1], demonstrated partial
and complete responses in about 50% of patients with metastatic
melanoma following adoptive transfer of ex vivo-expanded
autologous tumor-infiltrating T lymphocytes. Another example
of AIT success was illustrated by Yee and colleagues [2], in the
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currently limited to animal models and their success relies on the
successful stable transduction of the reporter gene and the
persistence of the reporter gene expression over time. A
combination of direct labeling strategy and optical imaging
methodology would be ideal, in terms of simplicity and cost
effectiveness, for monitoring cell trafficking in preclinical studies.
This could be extended to clinical investigations when a suitable
imaging nuclide, such as 124I or 19F, is included in the direct cell
labeling strategy.
Studies describing optical imaging of directly labeled immune
cells is quite limited [8]. However, using ex vivo imaging and other
in vitro protocols, several DNA-binding, cytoplasmic, covalent
coupling or membrane inserting fluorescent dyes have been
investigated for direct labeling of T lymphocytes to track
lymphocyte migration and proliferation [33]. Due to interference
from autofluorescence and tissue absorbance, most of these dyes
are not ideal for in vivo optical imaging and their use is limited to
ex vivo detection. The optical imaging window is primarily limited
by absorption, due to either blood at short wavelengths or water at
long wavelengths. This could be overcome by the use of nearinfrared dyes (NIR) that will allow deep tissue signal localization
[34]. The red/NIR tissue optical window between 600 and
1300 nm is the spectral region where light has its maximum depth
of penetration in tissues due to minimal absorption and scattering.
Among the various options available for direct labeling, the cell
membrane dyes retain the signal for relatively longer periods than
DNA-binding, cytoplasmic or covalent coupling dyes [33].
Therefore, a combination of NIR based fluorescent cell membrane
dyes would offer a direct labeling method for monitoring cell
trafficking while exploiting high sensitivity, simple labeling
technique, decreased autofluorescence and relatively low costs
[18].
In this study, using a lipophilic, NIR-fluorescent cyanine cell
membrane dye and a direct labeling method, we investigated the
tumor localization and migration of 4T1 tumor specific Tlymphocytes that were first activated in vitro with Bryostatin/
Ionomycin (B/I) and grown with Interleukin-2 (IL-2). We were
able to monitor up to three weeks post intravenous administration
of directly labeled T-lymphocytes in living animals by non-invasive
multispectral fluorescence imaging.

T-lymphocytes. However, during the development of such
methodologies it is often difficult to evaluate the functioning and
potency of the adoptively transferred T-cells in vivo. Tracking the
movement, proliferation and viability of re-infused tumor specific
T-lymphocytes, by multi-modality imaging in serial images at
different time points, during the treatment could define the
parameters that lead to successful AIT. To address these issues,
various non-invasive imaging methods to monitor immune cell
trafficking and activation are under development in various
laboratories [8–11]. Herein, we describe a simple near infra-red
(NIR) optical imaging method that allowed us to monitor the
tumor homing of adoptively transferred T-cells in an animal
model of breast cancer.
Noninvasive in vivo imaging of adoptively transferred Tlymphocytes requires an effective and mild labeling methodology
and the right imaging technology. Cell labeling methods for
imaging purposes can be classified as either direct or indirect [8].
Direct labeling enables the imaging of cells labeled ex vivo and
reinfused into the patient or subject who is being examined.
Radionuclide based direct labeling probes for SPECT/PET
imaging includes include, [111In]-Oxine, [18F-]FDG, [99mTc]HMPAO, and [64Cu]-PTSM. These have been used to monitor
the migration of T-lymphocytes in vivo [12–17]. However, these
techniques do not permit long term monitoring due to the short
physical half-life of the radionuclides, relatively low level of
radioactivity per cell, and in certain instances, are limited by
significant cell toxicity [18]. On the other hand, indirect labeling
utilizes imageable reporter protein/probe combinations and rely
on the ex vivo transduction of a relevant reporter gene into the
immune-competent cells. Following reinfusion of the transduced
cells into the subject, the product of the reporter gene can be
imaged by injecting a suitable radiolabeled substrate. Herpes
Simplex Virus Type-1 Thymidine Kinase (HSV1-tk) is such a PET
reporter gene (PRG) and is one of the most commonly used
indirect methods to image adoptively transferred T-lymphocytes in
animals and patients, and it can be imaged with various substrates
such as[124I]-FIAU, [131I]-FIAU, [18F]-FEAU and [18F]-FHBG
[19–26]. The sodium/iodide symporter (NIS) is another reporter
gene that has also been evaluated for imaging cells of the immune
system in immortalized macrophage cell lines genetically engineered to express NIS and GFP (RAW264.7/hNIS-GFP) [27].
Using [124I-NaI PET imaging, these investigators monitored
macrophage migration towards inflamed tissue. In addition to
[124I]-NaI; [99mTc]-04, [123I]-NaI, [125I]-NaI and [18F]-tetrafluoroborate can also be used as substrates for NIS [28].
Radionuclide based methods are useful in the clinic due to the
ability to image signals from deep tissues. However, the logistics of
radionuclide techniques are more demanding, which makes them
less cost effective for preclinical investigations. Non-radioactive
agents, such as fluorocarbon-based probes, have also been used for
efficient direct ex vivo labeling of cells, and used in conjunction
with 19F MRI for in vivo detection and imaging [29]. This
method, for in vivo monitoring of an autologous dendritic cell
vaccine to treat colorectal cancer, is currently being evaluated in
humans [30].
On the other hand, optical methods are relatively easy, require
simpler imaging equipment and are cost effective, but are not very
useful in the clinic due to the lack of effective technology that can
detect optical signal from deep tissues. However, optical labels,
both direct and indirect, could be very useful for research and
development of various strategies aimed at improving immune cell
therapy. One cost effective approach is to use optical reporter
proteins such as firefly or renilla luciferase to label the cells and
monitor them by optical imaging [31,32]. However, these are
PLOS ONE | www.plosone.org

Materials and Methods
Animals
Female BALB/c mice, aged between 8–12 weeks, obtained
from National Cancer Institute, Bethesda, MD, were caged in
groups of five or fewer, and provided with food and water ad
libitum. All animal experiments were performed according to the
policies and guidelines of the Institutional Animal Care and Use
Committee (IACUC) at Virginia Commonwealth University,
USA. All procedures were reviewed and approved by the VCU
IACUC prior to the conduct of the study. 2% Isoflurane in
Oxygen was used for anesthesia during imaging and all efforts
were made to minimize suffering. Animals were euthanized by
using controlled release of CO2 from a cylinder into a chamber
that allows good visibility of the animals and large enough to avoid
crowding.

Tumor cell lines
Murine mammary breast carcinoma (4T1) cell line was kindly
provided by Dr. Jane Tsai, Michigan Cancer Foundation, Detroit,
Michigan [35]. 4T1 cells were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) with 10% heat-inactivated fetal bovine
serum (Hyclone, Logan, UT) 1 mM sodium pyruvate, 100 U/ml
2
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penicillin, and 100 mg/ml streptomycin (Sigma, St. Louis MO).
Tumor cells were trypsinized with 0.05% trypsin-EDTA (Fisher,
Pittsburgh), washed with PBS and used for experiments.
Meth A sarcoma cells were obtained from American Type
Culture Collection (Rockville, MD) and grown in DMEM media,
containing 10% heat inactivated fetal bovine serum, 1 M sodium
pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin,
10 mM HEPES, and 2 mM L-glutamine in a humidified
incubator with 5% CO2, at 37uC. Cells .90% confluence were
used for experiments.

Diego, CA) and analyzed using Beckman Coulter Epics XLMCL flowcytometer and the data were analyzed using EXPO 32
software. Two different sets of experiments were performed to
verify the results.

Interferon-c release assay
In vitro. Interferon-c (IFN- c) released into supernatants of
4T1 sensitized and expanded T-lymphocytes in response to
stimulation with irradiated 4T1 and Meth-A cells (non-specific
control) was assayed using BD OptEIA mouse IFN-c ELISA kit
(BD Biosciences, San Jose, CA). T-cells obtained from popliteal
DLN, which had been activated and expanded in IL-2 containing
media, were collected on day 6 and incubated with DiR staining
solution (320 mg/ml). The DiR labeled and unlabeled cells were
collected 1 day and 7 days post-labeling and incubated with the
irradiated 4T1 or Meth-A tumor cells for 24 hrs, and the amount
of IFN-c in the supernatant was analyzed. As a negative control,
4T1 sensitized T cells alone were incubated under similar
conditions.
In vivo. Blood was collected from three different groups of
animals bearing: i) 10 day old 4T1 tumor, ii) 10 day old 4T1 tumor
and injected with 10 million DiR labeled T-cells/mouse, iii) 10 day
old Meth-A tumor and injected with similar number of activated
and DiR labeled T-cells. One week later, blood was collected and
the amount of the interferon-c in serum was determined by the
same kit and assay described above.

Isolation, activation and in vitro expansion of tumor
specific lymphocytes
Donor mice were vaccinated in the left hind footpad with viable
16106 4T1 cells. Ten days later, when these mice had a growing
tumor in the foot, popliteal draining lymph nodes (DLN) were
harvested under sterile conditions and disrupted through mesh
screens to yield single cell suspensions. The cells from DLN were
filtered and resuspended in complete RPMI media at 16106
cell/ml concentration. These cells were then activated by
incubating them with 5 nM Bryostatin 1 (Sigma, St. Louis MO),
1 mM Ionomycin (Calbiochem, San Diego, CA) and 80 U/ml IL2 (Chiron, Emeryville, CA) at 37uC for 18 hours. To expand the
lymphocyte population, cells were washed three times with warm,
complete RPMI and resuspended at 16106 cells/ml concentration
and incubated with 40 U/ml of IL-2. The cells were then allowed
to proliferate in culture for 6–13 days and were split every other
day to maintain 1–26106 cells/ml concentration. Fresh IL-2 was
added at each split. Cell proliferation was calculated by
determining the number of viable cells, on different days of
culture, by trypan blue exclusion and comparing it with the
number of cells on day 1 of expansion. Luminescence based cell
viability assays were also carried out as described below.

Animal model and lymphocyte trafficking
For the development of tumor models, mice were inoculated
subcutaneously into the right flank with either 4T1 cells or Meth-A
tumor cells (56104) and the tumor was allowed to grow for 10
days. To follow in vivo trafficking of T cells, 56106 4T1 sensitized
T-cells were first labeled with DiR (320 mg/ml staining solution).
The cells were then filtered through 70-mm nylon mesh strainer
and injected intravenously (iv) into the mouse tail vein (106106
cells in 0.5 ml PBS per mouse) either a week before the tumor cells
were injected or 10 days after tumor implantation. One day before
injection of DiR labeled T-lymphocytes, mice were pretreated,
intraperitoneally (ip), with 100 mg/kg Cyclophosphamide (CYP)
(Mead Johnson, Princeton, NJ). In order to understand the fate of
non-viable DiR labeled cells, parallel group of 4T1 tumor bearing
mice were injected with cell lysate derived from the DiR labeled Tlymphocytes.

Labeling of lymphocytes with NIR-fluorescent probe
Direct labeling of T- lymphocytes isolated on day-6 after in vitro
expansion was achieved by incubating the cells with 1,1dioctadecyltetramethyl indotricarbocyanine Iodide (DiIC18(7) or
DiR), a lipophilic Near-Infra red fluorescent dye (Absorption/
Emission: 748/780 nm) (PerkinElmer, MA). DiR stock solution
was prepared by dissolving 25 mg dye in 3 ml Ethanol. From this
stock, further dilutions were made to required concentrations in
media and incubated with cells for 30 minutes at 37uC. After
incubation, cells were spun down at 1000 rpm at 4uC for
10 minutes, then washed twice with PBS and used for experiments.

Multi-spectral fluorescence imaging
Fluorescent images were taken from day 1 to day 21 to monitor
the homing and localization of labeled T lymphocytes at the tumor
site. Multi-spectral fluorescence imaging system (Maestro-2 by
PerkinElmer, USA) was used to monitor DiR labeled Tlymphocyte trafficking and localization in host mice with and
without tumors. A NIR/Orange double filter setup (640 nm to
820 nm) and spectral unmixing was used for image acquisition and
processing. Image processing and data analysis were performed
using Maestro-2 software version 2.10. Images were obtained at
different time points (2 hours, 24 hours, 48 hours, 72 hours, 6days, 8-days, 10-days, 13-days, 15-days, 17-days, 20-days, and 21days) post-injection of labeled T-lymphocytes. Six mice per time
point were used; and four imaging positions, dorsal, ventral, left
and right sides, were used at each time point.

Cell viability assays
The highest tolerable concentration of DiR in the staining
solution, which can be used to label T-cells, was determined using
Cell Titer-Glo Luminescent assay kit (Promega, USA) and flow
cytometry. Tumor sensitized lymphocytes, cultured in media for 6
days in IL-2 containing media, were labeled with a staining
solution containing various concentrations (3.5, 14, 56, 224 and
320 mg/ml) of DiR. Following labeling, 25000 cells/100 ml were
plated in triplicates in a 96 well plates, and incubated along with
similar number of unlabeled cells in a humidified 37uC CO2
incubator. After 1, 4 or 7 days of incubation, the Cell Titer-Glo
reagent was added to the cells and the % Viability calculated for
each labeled group in comparison to unlabeled cells (100%
viability). For flow cytometry, DiR labeled and unlabeled T-cells (2
or 7 days post labeling) were double stained with propidium iodide
(PI) and AnnexinV-FITC (BD Biosciences Pharmingen, San
PLOS ONE | www.plosone.org

Immunohistochemistry
After imaging, mice were euthanized; organs and tumors were
collected, embedded in Optimal Cutting Temperature compound
3
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(O.C.T, Tissue-Tek, USA) and stored at 280uC. Using a cryostat
system (LEICA CM1850 UV), five-micron thick serial sections of
the tissue samples were collected onto glass slides. The sections
were fixed at room temperature for 15 min in 3% freshly prepared
paraformaldehyde in PBS (pH 7.4), and then washed three times
with 0.3M glycine in PBS. Antigen retrieval was done using heat
and citric acid buffer method. Following this, sections were washed
three times in PBS for 5 min each, then incubated with blocking
buffer (5% normal goat serum +0.1% Triton X-100 in PBS,
pH 7.4) for 1 hour at room temperature. Tissue sections were
incubated, overnight, at 4uC with Anti-F4/80 and Anti-CD69
primary antibodies (Abcam, USA), which were used to detect
macrophages and activated T cells respectively. This was followed
by incubation, for 1 hr at room temperature, with Alexa Fluor 488
goat anti-rat IgG and Alexa Fluor 568 Goat anti-hamster IgG
(Abcam, USA). The sections were cover-slipped and mounted with
Vectashield Mounting Medium (Vector Laboratories, Burlingame,
CA), and were then imaged and analyzed using a Zeiss LSM 700
confocal laser scanning microscope.

Figure 1. Percent viability of T cells labeled with various
concentrations of DiR measured using ATP based luminescent
assay. Bryostatin/Ionomycin (B/I) activated 4T1-cells grown in IL-2 were
labeled on day 6 of their ex vivo expansion, which is day-0 of labeling.
Viability of T-cells on 1, 4 and 7 days post-labeling were compared with
unlabeled cells on respective days and expressed as percent viability. Ttest was used to compare the significant differences (p,0.05) in the cell
viability between day 1 versus day 7 (*) and day 4 versus day 7 (#).
Average 6 SD from three different assays are shown in the graph.
doi:10.1371/journal.pone.0109162.g001

Statistical analysis
The significant differences in the ex vivo and in vivo studies
were determined using the equal variance analysis (ANOVA) (JMP
software), or Student’s t-test. P value of ,0.05 was considered as
statistically significant difference. The data shown in graphs are
mean 6 SEM.

labeling (day 10 of expansion). After that, the cell viability begins
to go down (day 7 post-labeling which is day 13 of ex vivo
expansion). These results showed that labeling of cells with DiR
does not affect the proliferation of the lymphocytes grown in the
presence of IL-2 even after 10 days of expansion.

Results
Viability of DiR labeled T lymphocytes
The viability of lymphocytes labeled with various concentrations
of DiR was assessed to determine the optimum non-toxic
concentration with which cells could be labeled. Since T cells,
which have been B/I activated and expanded in IL-2 containing
media for six days, were used for in vivo studies, the viability of
cells from day 6 onwards was monitored, when labeled with DiR
and compared with unlabeled T cells. The results show that there
are no significant differences in % Viability among the various
concentrations of DiR tested. However there is a significant
difference in the viability of cells recovered on days 1 and 4
compared to viability tested at day 7 post-labeling. Since on day 1
and 4 the cells were 80–90% viable even at the highest
concentration of DiR used (320 mg/ml), this concentration was
used for further in vitro and in vivo studies (Figure 1) as higher
amount of DiR on cell membranes is likely to allow signal
retention for relatively longer durations. Flow cytometry analysis
also confirmed that, at this concentration the efficiency of labeling
was .90% (Figure S1 in File S1). Tumor sensitized lymphocytes
were labeled with 320 mg/ml of DiR and on day 2 and 7 postlabeling, cells were taken and incubated with Annexin V/PI to
determine the cause of cell death. The flow cytometry results
showed that, the cell viability of unlabeled and labeled cells was
comparable.

Interferon-c production in vitro and in vivo
In vitro activated 4T1 sensitized T cells were expanded for 6
days, and incubated (either unlabeled or DiR-labeled) with
irradiated 4T1 tumor cells or Meth A tumor cells for 1 and 7
days in IL-2 containing media. The levels of IFN-c in the
supernatant were determined. The results showed that, with time
there is accumulation of IFN-c in the media but there is no
significant difference in the IFN-c levels in the supernatant of T
cells, incubated alone compared to T cells incubated with nonspecific Meth A tumor (Figure 3 panel A) on respective days.

Pre- and post-labeling Cell proliferation
The proliferation of 4T1 sensitized lymphocytes isolated from
tumor DLN activated with B/I and expanded in IL-2 containing
media was observed for 13 days. Since the number of lymphocytes
from day 6 was high (Figure 2), these were labeled with DiR to be
adoptively transferred into 4T1 bearing mice, and the effect of
labeling cells with DiR on proliferation was determined. The
results confirmed that, cells labeled with DiR showed similar
proliferation as the unlabeled T cells. Both unlabeled and labeled
cells continue to proliferate at the same rate until day 4 postPLOS ONE | www.plosone.org

Figure 2. Fold increase in cell numbers measured by viable cell
counts following ex vivo activation. Cell numbers were highest on
day 6 and this time point was selected for DiR labeling. Following
labeling, no significant differences (p,0.05) in cell proliferation
between DiR labeled and unlabeled cells were found.
doi:10.1371/journal.pone.0109162.g002
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NIR signal at the tumor site in mice injected with cell lysates
confirms that only viable cells home into the tumor (Figure 4B).
To determine whether signals from DiR labeled 4T1 sensitized
T cells can persist in vivo for a prolonged period of time and
respond to a later immunologic challenge, 4T1 tumor cells were
introduced one week after the mice had already received infusion
of activated/expanded T cells. Interestingly, the T cells migrated
to the site of tumor as early as 2 hours post injection of tumor cells
and the signals from DiR tagged T cells was detectable for more
than 2 weeks (Figure 5A). Further examination of the tumor/
background (BKG) ratio revealed that the signal intensity had
increased modestly on day 3 and then began to gradually decline
(Figure 5B).

However, T cells incubated with 4T1 tumor cells showed
significantly higher release of IFN-c into the media (p,0.05).
Since no significant differences in cytokine levels released were
observed between unlabeled and labeled T cells, the data also
demonstrate that labeling the cells with DiR does not affect their
interaction with tumor cells. Figure 3 panel B shows that, the
amount of IFN-c in the mice bearing 4T1 tumor which have been
injected with labeled T cells, is higher in their blood serum
compared with mice bearing 4T1 tumor only (no T cells infused)
and mice bearing Meth A and which have been injected with
labeled T cells.

Multi-spectral fluorescent imaging of T cell trafficking
Adoptive transfer of DiR labeled 4T1 sensitized T lymphocytes
which had been expanded in vitro for 6 days, were administrated
intravenously after 10 days of the tumor implantation. Imaging of
the mice using Maestro-2, revealed homing of 4T1 sensitized
lymphocytes to the site of 4T1 tumor (Figure 4A). The signals
from DiR labeled cells persisted in tumor bearing mice for up to
21 days (Figure S5A in File S1). The tumor/BKG ratio shows that
the peak signal intensity is obtained on day 3 after adoptive
transfer, following which the signal intensity started to gradually
diminish (Figure 4C). In contrast, when the 4T1 sensitized
lymphocytes were injected into Meth A tumor bearing mice,
there was no migration of DiR labeled cells to the tumor site
(Figure S5B & S5C in File S1). This is indicated by lack of
fluorescence signal obtained from the tumor site. The absence

Localization of labeled T-lymphocytes at non-tumor
tissues
To investigate the migration pattern of 4T1 sensitized T cells
following inoculation to sites besides the tumor site, tumor bearing
mice were dissected at various time points following inoculation
with DiR labeled T cells and different organs were removed and
imaged ex vivo. Besides tumor, labeled T lymphocytes were also
seen to have localized to liver, spleen, lungs, and bone marrow, as
shown in Figure 6. The maximum fluorescent signals from labeled
T-lymphocytes in these organs were observed on days 7, 10 and 16
post-injection of labeled T-cells. The signal increased modestly
with time, which would indicate that additional labeled cells were
migrating to these sites or that the T-cells are proliferating over
time at these organs.

Immunohistochemistry confirmation of activated T cells
at tumor site
To confirm the localization of the activated T-lymphocytes to
the tumor site, 5 micron thick tumor sections from mice
inoculated with DiR labeled T-cells were stained for CD69 and
F4/80 to detect activated T-lymphocytes and macrophages
respectively. Both activated T lymphocytes and macrophages
were visualized at the tumor site as shown in Figure 7. Different
sections of the tumor from outside to deep inside the tumor were
analyzed. The activated T lymphocytes were mostly localized at
the superficial layer of the tumor; macrophages were localized
deeper inside the tumor tissues. To ensure that the localization of
macrophages at the tumor site was not to attack and engulf labeled
activated T-lymphocytes and behaves against these cells as foreign
bodies, we implanted 4T1 breast carcinoma tumor in a number of
mice and dissected them after 10 days when they have the same
tumor size as in our previous experiments. These mice were not
injected with activated T lymphocytes. Tumors were sectioned,
double stained for CD69 and F4/80 and then imaged. Figure 7 C
and D illustrate the images of these sections, and we did not see
any activated T cells at these tumors and this was expected.

Discussion
The present study demonstrates a simple optical imaging
method to monitor T-lymphocytes that are sensitized to 4T1
murine breast carcinoma, and adoptively transferred to recipient
mice bearing 4T1 tumors. Following transfer, tumor localization
of the 4T1 specific T-lymphocytes started as early as 2 hours after
intravenous administration and peaked at 3 days post administration of the activated cells. We also observed, from ex vivo imaging
of dissected organs, that the labeled T-cells move into lymphoid
organs such as bone marrow and spleen. Furthermore, we
observed that when labeled 4T1 specific T cells were injected
into non-tumor bearing mice, they migrated to 4T1 tumor cells

Figure 3. Interferon-gamma assay. The amount of interferongamma (IFN- c) released into the supernatant (A) and in the mouse
serum (B) by the 4T1 specific T lymphocytes are shown (mean 6 SD).
This demonstrates the 4T1 cell specificity and functioning of T
lymphocytes are unaffected, both in vitro as well as in vivo, by the
DiR labeling.
doi:10.1371/journal.pone.0109162.g003

PLOS ONE | www.plosone.org
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Figure 4. NIR fluorescence imaging of IL-2 grown T-cell trafficking. Homing of 4T1 sensitized DiR labeled viable cells to 4T1 tumor site was
seen as early as 2 hours post T-cell administration (A). Fluorescent signal was not detected at the tumor site in animals injected with the cell lysates of
DiR labeled IL-2 grown T-cells (B). Quantitation of Tumor/Background ratios show, T-cells localized at the tumor site from 2 hours posts T-cell
administration, peaked on day 3 and persisted up to 14 days in the animal (C). While in case of IL-2 lysate, there was no localization of 4T1 specific T
cells at the tumor site.
doi:10.1371/journal.pone.0109162.g004

Figure 5. T-cell trafficking following delayed immunologic challenge. 4T1 sensitized T cells expanded in IL-2 containing media, were
injected in naive mice one week prior to 4T1 challenge. (A) The labeled 4T1 specific T cells were able to leave the lymphoid compartments and
localize within 2 hours at the site of an immunologic challenge induced by 4T1 cell implantation in the flank. (B) Tumor/Background ratios obtained
from mice injected with T cells and implanted with 4T1 cells a week later.
doi:10.1371/journal.pone.0109162.g005
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Figure 6. Ex vivo validation of mice injected with viable cells or T cell lysate. NIR signal from organs harvested from mice show 4T1 tumor
specific accumulation of viable 4T1 sensitized T-lymphocytes, which is absent with T cell lysates.
doi:10.1371/journal.pone.0109162.g006

breast cancer model. The DiR based direct cell membrane
labeling might be a simple method that could help accelerate
preclinical research in the area of immune cell homing to solid
tumors. However, this method is not without some limitations, as
discussed below.
A potential drawback of using a cell membrane dye is the
possibility of dye transfer and cross labeling of neighboring cells
both in vitro and in vivo [38]. Results from our initial in vitro
experiments showed that such transfer of dye did not occur. This
was confirmed by the lack of a fluorescent signal from 4T1 tumor
cells, after these cells were incubated along with DiR labeled 4T1
sensitized T-cells for 24 hrs. (Figure S2 in File S1). Fluorescence
detection of DiR in the liver, heart and 4T1 tumor obtained from
mice injected with only the DiR dye revealed the presence of
fluorescence only in the liver and not in the tumor or heart (Figure
S4 in File S1) suggesting its retention in the liver for metabolism.
Further, when lysates of DiR labeled cells are injected into 4T1
tumor bearing mice, NIR signal at the tumor site was absent. This
observation suggested to us that the signal observed at the tumor
site originated from the DiR labeled T-cells. These results and the
results from ex vivo assays, including flowcytometry analysis which
shows lack of significant DiR signal associated with macrophages
and CD452 non-immune cells (Figure S3 in File S1), confirm that
the NIR signal emanating from the tumor site pertains to DiR
labeled activated T-cells. Thus trafficking of tumor specific T-cells
can be non-invasively monitored by the direct labeling of T-cells
with DiR. Adding further support are reports by other investigators who have also used similar techniques to monitor cellular
therapy without any hindrance from non-specific transfer of the
dye [39]. For the applications described in the present study, the
small degree of dye transfer that may occur toward the
neighboring cells does not appear to be a limiting issue.
Having demonstrated the utility of this imaging method to show
localization and persistence of labeled T-cells at the 4T1 tumor
sites, we wanted to verify that the T cells retained at the tumor do
actually inhibit 4T1 tumor growth. Our data (Figure S6 in File S1)
show significant inhibition of 4T1 tumors into which labeled Tcells migrated, similar to unlabeled 4T1 specific T-cells. Furthermore we show that this inhibition is specific to 4T1 tumors because
we demonstrate that inhibition of tumor growth was not observed
in Meth-A tumor, to which 4T1 T-cells are not specific. Similar

that were implanted a week later. DiR labeled 4T1 specific T-cells
were detected as early as 2 hours at the site of tumor cell injection.
The signal at the tumor site persisted for another two weeks,
confirming that the labeled T-cells can move out of the lymphoid
organs to the site of a fresh antigen challenge. The use of DiR have
been reported by other groups, where DiR was successfully used to
stain human leukemia G2L cells, mouse lymphocytes and rat red
blood cells for in vivo tracer experiments [36]. DiR was also used
to label fibroblast cells, which were then observed to be targeting
ovarian tumor some distance away from the injection site [37]. We
are quite encouraged by the results of the present study in the

Figure 7. Histologic evaluation of T-cell accumulation in 4T1
tumors. 4T1 tumor bearing mice were injected with activated T-cells
and the tumor sections were stained for CD69 activated T-cells (red
color) marker and F4/80 macrophage (green color) marker (Figures-A &
B). Images of 4T1 tumor sections obtained from mouse bearing 4T1
tumor but not injected with activated T cells, stained for CD69 and F4/
80 markers (Figures-C & D).
doi:10.1371/journal.pone.0109162.g007
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of labeled cells was comparable to unlabeled cells, similar to our
observations.
The in vivo biodistribution of the labeled T-lymphocytes, in this
study, was consistent with other studies. The NIR signal was
detected in lungs, spleen, liver, bone marrow and was observed at
the tumor site at 24 hours and remained stable for up to 21 days
when the labeled cells were infused into mice bearing established
4T1 breast carcinoma tumors. To ascertain whether the source of
signal around the tumor was coming from labeled T-cells, double
staining of tumor with CD69 (T cell activation marker) and F4/80
(macrophage marker), was performed. The confocal microscopy
images revealed presence of activated T cells only in sections from
mice bearing 4T1 tumor injected with ex vivo activated T cells and
not in tumor sections from control 4T1 bearing mice. On the
other hand, the presence of macrophages was observed in tumor
sections from both groups of animals as expected. However, it is
quite possible that a portion of the signal from lungs, spleen, liver
and bone marrow could emanate from T-cells that were labeled
with DiR, but died at some point following in vivo administration.
Because a portion of the DiR labeled cell lysate was observed to be
accumulating in these organs. This could impede the interpretation of images if the targeted tumors are located in any of these
organs. However, it should be noted that the signal coming from
the viable cells three days post injection are at least one fold
greater than the signal coming from the dead cells. Such intense
signal at the tumor site could serve as a clue to distinguish tumor
specific localization from non-specific accumulation.
In conclusion, this study shows that, labeling of 4T1 specific T
lymphocytes with DiR, a NIR fluorescent cell membrane marker,
provides an easy to use, relatively stable and convenient tool for in
vivo imaging of T-lymphocytes whilst retaining their inherent
function. Use of DiR or similar cell membrane markers will be
useful for investigating lymphocyte trafficking following their ex
vivo sensitization, activation and proliferation. This method could
also be used to non-invasively monitor the trafficking of other cell
types. We are encouraged by our findings and recommend the use
of this technique by other investigators, to further evaluate and
utilize this strategy. When appropriate validations are included,
this method could be easily adopted for preclinical research
without the need of sophisticated radionuclide imaging facilities.

findings were observed by Cha and coworkers, who showed that
4T1 specific T cells grown in IL-2 media are able to inhibit 4T1
tumor growth [40].
Tracking of cells using genetically encoded markers has its own
shortcomings. Currently, PET reporter gene imaging of transduced cells appears to be best suited for in vivo and clinical
applications. Herpes simplex virus type 1 thymidine kinase
(HSV1-tk) and its mutant HSV1-sr39tk are the most widely used
PET reporter genes and have been extensively studied for cell and
gene therapy [41]. However, PET imaging of reporter genes
involves the administration of a radioactive probe that is selectively
trapped inside the cells. Since HSV1-tk is a protein of viral origin,
in humans, immune reactions against it are a serious concern for
its use in transplanted cells that are intended to survive for longer
periods [42,43]. Furthermore, currently available reporter probes
for HSV1-tk or HSV1-sr39tk are also phosphorylated, to a small
degree, by mammalian thymidine kinases. Therefore, some nonspecific uptake of these reporter probes are seen in rapidly
proliferating mammalian cells, such as cancer cells, which will
limit the detection of lymphocytes expressing HSV1-sr39tk within
the tumor tissue [24]. Currently available radiolabeled probes for
PET reporter genes have unfavorable biologic clearance properties
(high background in the abdominal region) or have other physical
properties (non-pure positron-emitting isotope and/or long
physical half-life of the radiolabel) that are not ideal for PET
imaging [42]. Transgene delivery to dividing and non-dividing
cells is not easy. Despite several advances in transgene delivery
methods, the transduction of primary human T cells is still
challenging and methods to achieve efficient gene transfer are
often expensive and time-consuming. Considering the above, it is
evident that gene based cell imaging techniques are also not
without limitations.
Smirnov and colleagues [44], studied in vivo T cell trafficking
by direct labeling with SPIONs for MRI imaging. Their results
showed relatively lower signal in the spleen at 24 hours than at
48 hours. The signal in spleen and tumor then peaked at 72 hours.
In another study done by Pittet and colleagues [45], it was shown
that tumor specific cytotoxic T-lymphocytes directly labeled with
111
In-Oxine (2.8 days half-life) for SPECT imaging, started
localizing at the tumor site within the first 24 hours and continued
to increase over time and were at peak when imaged at 120 hours
post injection. Labeling of T-cells with near-infra red (NIR)
fluorescent dyes for AIT has been reported in a few recently
published studies. Du and coworkers [39], investigated the
trafficking of DiR labeled human cytokine-induced killer (CIK)
cells and cytotoxic T lymphocytes (CTLs) in a nude mouse model
of orthotopic gastric carcinoma. In their study, the fluorescent
signal peaked at 48 hours and concentrated fluorescence signals
was observed at the tumor site, up to two weeks after infusion. Our
results are consistent with these reports; and moreover, the NIR
signal from the T-cells at the tumor site persisted for nearly three
weeks after labeling and administration. This also demonstrates
the suitability of this method for relatively long-term studies.
After labeling the T-cells with a range of DiR concentrations,
we tested the cell viability using two different methods to ensure
good cell tolerance to the dye before moving to the in vivo studies.
T-cell function was also tested by measuring IFN-c release in
response to tumor antigen, and our results showed no significant
detrimental effect of the labeling probe on cell proliferation,
viability or function. Also, this allowed us to use a high DiR
concentration (320 mg/ml) in the labeling solution. Our study also
demonstrates persistence of signal associated with labeled T-cells
even 3 weeks post labeling under the in vivo conditions of living
mice. In the study by Du and coworkers [39], the cell proliferation
PLOS ONE | www.plosone.org

Supporting Information
File S1 This file contains Figure S1–Figure S6. Figure S1:
DiR labeled T cells were analyzed by flowcytometry showing the
mean fluorescent intensity (MFI) is markedly high with DiR
labeled CD3 positive T cells and the labeling efficiency with DiR
was 94 %. Figure S2: DiR labels T cells with negligible transfer to
tumor cells. DiR labeled T cells incubated with 4T1 tumor cells for
24 hrs, showed negligible to no transfer of dye to 4T1 cells. Figure
S3: Confirmation of immunohistochemistry results by flowcytometry. Panel-A tissues were stained for macrophages (F4/80),
panel-B tissues were stained for immune cell marker CD45. Both
confirm that DiR is linked to T cells and not transferred to other
cells. Figure S4: Unmixed fluorescent images of liver, heart and
4T1 tumor sections of animal injected with DiR only. From the ex
vivo imaging higher signal was detected in the liver and no signal
was in the heart, that is why liver was used as positive and heart
negative controls. 4T1 tumor section showed no signal of DiR
indicating that, the signal detected at the tumor site is correlated to
DiR labeled cells. Figure S5: Fluorescence imaging of T cell
trafficking. Homing of 4T1 sensitized DiR labeled T cells to (Panel
A) 4T1 tumor site (green color codes for Autofluorescence signal,
and red color codes for DiR signal), (Panel B) Meth-A carcinoma
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inhibition when these T cells were used against Meth-A tumors in
mice.
(PDF)

tumor site (used as negative control tumor) 4 days after the tumors
have been implanted. Red color indicates the signal from the NIR
DiR Dye used to label the T cells. (C) Tumor/Background ratios
graph showed that, cells localized at the tumor site on day 1
peaked on day 6 and persisted up to 21 days in the animal. While
in case of Meth A tumor, there was no localization of 4T1 specific
T cells at the tumor site. Figure S6: T cells with and without DiR
labeling inhibit 4T1 tumor growth in mice (n = 6/group). (A)
Untreated control (Ctrl 4T1) and Cyclophosphamide (CYP) only
groups (CYP 4T1) showed increase in the 4T1 tumor volumes
over time, while mice treated with CYP and 4T1 sensitized T cells
(CYP AIT 4T1) inhibited 4T1 tumor growth. This function was
unaffected by DiR labeling of the 4T1 sensitized T cells (CYP AIT
4T1 DiR). (B) The specificity of the 4T1 sensitized T cells against
4T1 tumor is demonstrated by the absence of tumor growth
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